skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 539,001  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Refined by: Database: ProQuest Central remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Material Type:
Article
Add to My Research

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Nature (London), 2021-04, Vol.592 (7853), p.283-289 [Peer Reviewed Journal]

Copyright Nature Publishing Group Apr 8, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03275-y ;PMID: 33524990

Full text available

2
Correction: Evolution and consequences of individual responses during the COVID-19 outbreak
Material Type:
Article
Add to My Research

Correction: Evolution and consequences of individual responses during the COVID-19 outbreak

PloS one, 2023-10, Vol.18 (10), p.e0292775-e0292775 [Peer Reviewed Journal]

COPYRIGHT 2023 Public Library of Science ;2023 Abbas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 Abbas et al 2023 Abbas et al ;2023 Abbas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0292775

Full text available

3
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Material Type:
Article
Add to My Research

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine, 2021-05, Vol.384 (20), p.1885-1898 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2102214 ;PMID: 33725432

Digital Resources/Online E-Resources

4
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Material Type:
Article
Add to My Research

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

BMJ (Online), 2021-05, Vol.373, p.n1088-n1088 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. BMJ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj.n1088 ;PMID: 33985964

Full text available

5
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Material Type:
Article
Add to My Research

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Nature (London), 2021-05, Vol.593 (7857), p.130-135 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03398-2 ;PMID: 33684923

Full text available

6
Correction: Predictors of post-COVID symptoms in Egyptian patients: Drugs used in COVID-19 treatment are incriminated
Material Type:
Article
Add to My Research

Correction: Predictors of post-COVID symptoms in Egyptian patients: Drugs used in COVID-19 treatment are incriminated

PloS one, 2022-07, Vol.17 (7), p.e0271154-e0271154 [Peer Reviewed Journal]

COPYRIGHT 2022 Public Library of Science ;2022 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 The PLOS ONE Staff 2022 The PLOS ONE Staff ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0271154 ;PMID: 35789344

Full text available

7
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Material Type:
Article
Add to My Research

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Nature reviews. Immunology, 2022-01, Vol.22 (1), p.57-65 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;COPYRIGHT 2022 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-021-00662-4 ;PMID: 34876702

Full text available

8
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Material Type:
Article
Add to My Research

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Nature medicine, 2021-11, Vol.27 (11), p.2032-2040 [Peer Reviewed Journal]

2021. The Author(s). ;COPYRIGHT 2021 Nature Publishing Group ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01540-1 ;PMID: 34588689

Full text available

9
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
Material Type:
Article
Add to My Research

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

The Lancet (British edition), 2021-05, Vol.397 (10289), p.2043-2046 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01115-6 ;PMID: 33991480

Full text available

10
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Material Type:
Article
Add to My Research

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

The Lancet (British edition), 2022-01, Vol.399 (10321), p.237-248 [Peer Reviewed Journal]

2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02753-7 ;PMID: 34953526

Full text available

11
A pooled testing strategy for identifying SARS-CoV-2 at low prevalence
Material Type:
Article
Add to My Research

A pooled testing strategy for identifying SARS-CoV-2 at low prevalence

Nature (London), 2021-01, Vol.589 (7841), p.276-280 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Jan 14, 2021 ;ISSN: 0028-0836 ;ISSN: 1476-4687 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-020-2885-5 ;PMID: 33086375

Full text available

12
Synchronous, Group Virtual Delivery of a Childhood Weight Program: Participation and Effectiveness
Material Type:
Article
Add to My Research

Synchronous, Group Virtual Delivery of a Childhood Weight Program: Participation and Effectiveness

Obesity (Silver Spring, Md.), 2021-12, Vol.29, p.168-169 [Peer Reviewed Journal]

Copyright Blackwell Publishing Ltd. Dec 2021 ;ISSN: 1930-7381 ;EISSN: 1930-739X

Full text available

13
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Material Type:
Article
Add to My Research

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

New England Journal of Medicine, 2021-06, Vol.384 (23), p.2187-2201 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2101544 ;PMID: 33882225

Digital Resources/Online E-Resources

14
Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study
Material Type:
Article
Add to My Research

Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study

Journal of medical Internet research, 2020-12, Vol.22 (12), p.e24286-e24286 [Peer Reviewed Journal]

Lori Ann Post, Tariq Ziad Issa, Michael J Boctor, Charles B Moss, Robert L Murphy, Michael G Ison, Chad J Achenbach, Danielle Resnick, Lauren Nadya Singh, Janine White, Joshua Marco Mitchell Faber, Kasen Culler, Cynthia A Brandt, James Francis Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.12.2020. ;Copyright Gunther Eysenbach MD MPH, Associate Professor Dec 2020 ;Lori Ann Post, Tariq Ziad Issa, Michael J Boctor, Charles B Moss, Robert L Murphy, Michael G Ison, Chad J Achenbach, Danielle Resnick, Lauren Nadya Singh, Janine White, Joshua Marco Mitchell Faber, Kasen Culler, Cynthia A Brandt, James Francis Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.12.2020. 2020 ;ISSN: 1438-8871 ;ISSN: 1439-4456 ;EISSN: 1438-8871 ;DOI: 10.2196/24286 ;PMID: 33216726

Full text available

15
Considerations in boosting COVID-19 vaccine immune responses
Material Type:
Article
Add to My Research

Considerations in boosting COVID-19 vaccine immune responses

The Lancet (British edition), 2021-10, Vol.398 (10308), p.1377-1380 [Peer Reviewed Journal]

2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;2021. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02046-8 ;PMID: 34534516

Full text available

16
Big data and simple models to track COVID-19
Material Type:
Article
Add to My Research

Big data and simple models to track COVID-19

Nature (London), 2021-01, Vol.589 (7840), p.26-28 [Peer Reviewed Journal]

Copyright Nature Publishing Group Jan 7, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-020-02964-4

Full text available

17
Seasonal coronavirus protective immunity is short-lasting
Material Type:
Article
Add to My Research

Seasonal coronavirus protective immunity is short-lasting

Nature medicine, 2020-11, Vol.26 (11), p.1691-1693 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2020. ;ISSN: 1078-8956 ;ISSN: 1546-170X ;EISSN: 1546-170X ;DOI: 10.1038/s41591-020-1083-1 ;PMID: 32929268

Full text available

18
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Material Type:
Article
Add to My Research

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

New England Journal of Medicine, 2022-03, Vol.386 (13), p.1207-1220 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2118691 ;PMID: 35172051

Digital Resources/Online E-Resources

19
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Material Type:
Article
Add to My Research

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

The lancet oncology, 2021-06, Vol.22 (6), p.765-778 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00213-8 ;PMID: 33930323

Full text available

20
Annals Graphic Medicine - What I Learned From COVID-19 (Until Now)
Material Type:
Article
Add to My Research

Annals Graphic Medicine - What I Learned From COVID-19 (Until Now)

Annals of Internal Medicine, 2020-06 [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://annals.org/aim/pages/conditions-of-use ;DOI: 10.7326/G20-0045

Digital Resources/Online E-Resources

Results 1 - 20 of 539,001  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (245,232)

Refine My Results

Creation Date 

From To
  1. Before 2004  (12)
  2. 2004 To 2013  (7)
  3. 2014 To 2017  (13)
  4. 2018 To 2022  (465,173)
  5. After 2022  (73,750)
  6. More options open sub menu

Language 

  1. English  (533,690)
  2. Japanese  (10,089)
  3. Spanish  (3,822)
  4. Portuguese  (3,516)
  5. French  (1,617)
  6. Turkish  (1,013)
  7. German  (889)
  8. Chinese  (553)
  9. Polish  (287)
  10. Italian  (255)
  11. Norwegian  (244)
  12. Afrikaans  (238)
  13. Russian  (163)
  14. Romanian  (153)
  15. Hungarian  (148)
  16. Slovenian  (115)
  17. Croatian  (97)
  18. Ukrainian  (94)
  19. Dutch  (93)
  20. Malay  (77)
  21. More options open sub menu

Searching Remote Databases, Please Wait